Outlook Therapeutics' Q3 earnings report shows no change in losses per share compared to the same period last year. This indicates that the company's financial performance has remained stable, which could be interpreted as neither particularly positive nor negative news by investors. Therefore, the short-term impact on the stock price is likely to be neutral.